Online emotion regulation treatment for maladaptive anger inhibition - an open-label pilot with a pooled interrupted time series design.

Cogn Behav TherAug 4, 2025 (epub)
Clinical ResearchPsychiatry

Johannes Larsson, Olivia Ojala, Johan Bjureberg et al.

✦ AI-curated · Sources linked

In 30 seconds

This open-label pilot evaluated a therapist-supported, 4-week online emotion-regulation treatment in 38 participants with elevated maladaptive anger inhibition. Using a pooled interrupted time series design, investigators compared outcomes across 4-week baseline and treatment phases. Feasibility and acceptability were supported by high retention and adherence, minor adverse events, and high credibility and satisfaction ratings. Piecewise growth curve analyses found significant, large immediate changes in anger inhibition (d = 1.26), anger rumination (d = 0.80), and anger assertion (d = 0.79); small additional gains were observed at 3-month follow-up. The authors conclude that randomised evaluation is warranted.

Key findings

  • Immediate change in anger inhibition was large (d = 1.26) when baseline and treatment phases were compared.
  • Anger rumination and anger assertion also showed large immediate changes (d = 0.80 and d = 0.79, respectively).
  • Retention and adherence were high, adverse events were minor, and participants reported high treatment credibility and satisfaction.
  • Small additional gains were observed at 3-month follow-up.

Why it matters

Maladaptive anger inhibition has documented risks, yet few treatments specifically target it. This pilot suggests that a brief, therapist-supported online approach can be delivered with good engagement and may improve anger-related measures. The findings provide preliminary support for further testing, while the design does not establish efficacy as securely as a randomised controlled trial.

What to keep in mind

The open-label pilot used a pooled interrupted time series design without a randomised comparator; the authors state that an RCT is needed.

Source

Published in Cogn Behav Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.